Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL002 in Early Alzheimer's Disease
NCT04592874Phase 2Completed
- Sponsor
- Alector
- Start
- Jan 2021
- Primary completion
- Aug 2024
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 2 trial of AL002 in Alzheimer's disease (AD), sponsored by Alector. Started Jan 2021; status: completed.
02
Drugs
AL002
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04592874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04592874.